UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 221

Sortiert nach

Biological subtypes of breast cancer: current concepts and implications for recurrence patterns

The quarterly journal of nuclear medicine and molecular imaging, 2013-12, Vol.57 (4), p.312

2013

Volltextzugriff (PDF)

Serum HER2 extracellular domain in metastatic breast cancer patients treated with weekly trastuzumab and paclitaxel: association with HER2 status by immunohistochemistry and fluorescence in situ hybridization and with response rate

Annals of oncology, 2005-02, Vol.16 (2), p.234-239

2005

Volltextzugriff (PDF)

A phase I study of dasatinib and weekly paclitaxel for metastatic breast cancer

Annals of oncology, 2011-12, Vol.22 (12), p.2575-2581

2011

Volltextzugriff (PDF)

Atypical femur fractures associated with use of bisphosphonates and denosumab

Annals of oncology, 2015-04, Vol.26 (4), p.819-820

2015

Volltextzugriff (PDF)

Phase I Dose-Finding Study of Weekly Docetaxel Followed by Flavopiridol for Patients with Advanced Solid Tumors

Clinical cancer research, 2007-10, Vol.13 (19), p.5841-5846

2007

Volltextzugriff (PDF)

Molecular profiling of oral microbiota in jawbone samples of bisphosphonate-related osteonecrosis of the jaw

Oral diseases, 2012-09, Vol.18 (6), p.602-612

2012

Volltextzugriff (PDF)

Identification of a serum-detectable metabolomic fingerprint potentially correlated with the presence of micrometastatic disease in early breast cancer patients at varying risks of disease relapse by traditional prognostic methods

Annals of oncology, 2011-06, Vol.22 (6), p.1295-1301

2011

Volltextzugriff (PDF)

Epothilones in breast cancer: review of clinical experience

Annals of oncology, 2007-07, Vol.18 (suppl-5), p.v16-v21

Fornier, MN

2007

Volltextzugriff (PDF)

Weekly Trastuzumab and Paclitaxel Therapy for Metastatic Breast Cancer With Analysis of Efficacy by HER2 Immunophenotype and Gene Amplification

Journal of clinical oncology, 2001-05, Vol.19 (10), p.2587-2595

2001

Volltextzugriff (PDF)

An automatic collector to monitor insoluble atmospheric deposition: application for mineral dust deposition

Atmospheric measurement techniques, 2015-07, Vol.8 (7), p.2801-2811

2015

Volltextzugriff (PDF)

A phase II study of ixabepilone and trastuzumab for metastatic HER2-positive breast cancer

Annals of oncology, 2013-07, Vol.24 (7), p.1841-1847

2013

Volltextzugriff (PDF)

Variability of mineral dust deposition in the western Mediterranean basin and south-east of France

Atmospheric chemistry and physics, 2016-07, Vol.16 (14), p.8749-8766

2016

Volltextzugriff (PDF)

Abstract P6-20-03: Tumor epichaperome expression using 124I PU-H71 PET (PU-PET) as a biomarker of response for PU-H71 plus nab-paclitaxel in HER2 negative (HER2-) metastatic breast cancer (MBC)

Cancer research (Chicago, Ill.), 2019-02, Vol.79 (4_Supplement), p.P6-P6-20-03

2019

Volltextzugriff (PDF)

Trastuzumab in combination with chemotherapy for the treatment of metastatic breast cancer

Seminars in oncology, 2000-12, Vol.27 (6), p.38-45

2000

Volltextzugriff (PDF)

Osteonecrosis of the Maxilla and Mandible in Patients with Advanced Cancer Treated with Bisphosphonate Therapy

The oncologist (Dayton, Ohio), 2008-08, Vol.13 (8), p.911-920

2008

Volltextzugriff (PDF)

70P Development and validation of a machine learning (ML) nomogram to predict RSClin results and guide adjuvant treatment of node-negative (N0) hormone receptor-positive (HR+)/human epidermal growth factor receptor-negative (HER2-) early breast cancer (eBC) in Europe

ESMO open, 2024-05, Vol.9, p.103076, Article 103076

2024

Volltextzugriff (PDF)

Dose-dense adjuvant chemotherapy for primary breast cancer

Breast cancer research : BCR, 2005-01, Vol.7 (2), p.64-69, Article 64

2005

Volltextzugriff (PDF)

Soluble interleukin-2 receptors (sIL-2R) in Hodgkin's disease: outcome and clinical implications

British journal of cancer, 1998-03, Vol.77 (6), p.992-997

1998

Volltextzugriff (PDF)

Clinical utility of serum HER2/neu in monitoring and prediction of progression-free survival in metastatic breast cancer patients treated with trastuzumab-based therapies

Breast cancer research : BCR, 2005-01, Vol.7 (4), p.R436-R443, Article R436

2005

Volltextzugriff (PDF)

Epothilones in breast cancer : review of clinical experience: Update on epothilones - novel microtubule stabilizing agents under clinical development

Annals of oncology, 2007, Vol.18

FORNIER, M. N

2007

Volltextzugriff (PDF)

Abstract PD5-04: Ki67 changes and PEPI score in the LORELEI trial: A phase II randomized, double-blind study of neoadjuvant letrozole plus taselisib versus letrozole plus placebo in postmenopausal women with ER-positive/HER2-negative early-stage breast cancer

Cancer research (Chicago, Ill.), 2018-02, Vol.78 (4_Supplement), p.PD5-04-PD5-04

2018

Volltextzugriff (PDF)

Doxorubicin followed by sequential paclitaxel and cyclophosphamide versus concurrent paclitaxel and cyclophosphamide: 5-year results of a Phase II randomized trial of adjuvant Dose-dense chemotherapy for women with node-positive breast carcinoma

Clinical cancer research, 2001-12, Vol.7 (12), p.3934-3941

2001

Volltextzugriff (PDF)

Incidence of chemotherapy‐induced, long‐term amenorrhea in patients with breast carcinoma age 40 years and younger after adjuvant anthracycline and taxane

Cancer, 2005-10, Vol.104 (8), p.1575-1579

2005

Volltextzugriff (PDF)

Phase II study of gemcitabine, trastuzumab, and pertuzumab for HER2-positive metastatic breast cancer after prior pertuzumab-based therapy

Annals of oncology, 2016-10, Vol.27, p.vi84-vi84

2016

Volltextzugriff (PDF)

Neoadjuvant letrozole plus taselisib versus letrozole plus placebo in postmenopausal women with oestrogen receptor-positive, HER2-negative, early-stage breast cancer (LORELEI): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial

The lancet oncology, 2019-09, Vol.20 (9), p.1226-1238

2019

Volltextzugriff (PDF)

1 – 25 von 221

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(193)
Mit Volltextzugriff
(193)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(91)
Life Sciences & Biomedicine
(83)
Humans
(72)
Female
(48)
Biological And Medical Sciences
(40)
Oncology
(37)
Middle Aged
(32)
Adult
(31)
Medical Sciences
(28)
Aged
(27)
Male
(27)
Saccharomyces Cerevisiae
(24)
Saccharomyces Cerevisiae - Genetics
(22)
Biochemistry & Molecular Biology
(21)
Breast Neoplasms - Drug Therapy
(21)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(18)
Base Sequence
(18)
Life Sciences
(18)
Pharmacology. Drug Treatments
(17)
Breast Neoplasms - Pathology
(16)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Biological subtypes of breast cancer: current concepts and implications for recurrence patterns

Serum HER2 extracellular domain in metastatic breast cancer patients treated with weekly trastuzumab and paclitaxel: association with HER2 status by immunohistochemistry and fluorescence in situ hybridization and with response rate

A phase I study of dasatinib and weekly paclitaxel for metastatic breast cancer

Atypical femur fractures associated with use of bisphosphonates and denosumab

Phase I Dose-Finding Study of Weekly Docetaxel Followed by Flavopiridol for Patients with Advanced Solid Tumors

Molecular profiling of oral microbiota in jawbone samples of bisphosphonate-related osteonecrosis of the jaw

Identification of a serum-detectable metabolomic fingerprint potentially correlated with the presence of micrometastatic disease in early breast cancer patients at varying risks of disease relapse by traditional prognostic methods

Epothilones in breast cancer: review of clinical experience

Weekly Trastuzumab and Paclitaxel Therapy for Metastatic Breast Cancer With Analysis of Efficacy by HER2 Immunophenotype and Gene Amplification

An automatic collector to monitor insoluble atmospheric deposition: application for mineral dust deposition

A phase II study of ixabepilone and trastuzumab for metastatic HER2-positive breast cancer

Variability of mineral dust deposition in the western Mediterranean basin and south-east of France

Abstract P6-20-03: Tumor epichaperome expression using 124I PU-H71 PET (PU-PET) as a biomarker of response for PU-H71 plus nab-paclitaxel in HER2 negative (HER2-) metastatic breast cancer (MBC)

Trastuzumab in combination with chemotherapy for the treatment of metastatic breast cancer

Osteonecrosis of the Maxilla and Mandible in Patients with Advanced Cancer Treated with Bisphosphonate Therapy

70P Development and validation of a machine learning (ML) nomogram to predict RSClin results and guide adjuvant treatment of node-negative (N0) hormone receptor-positive (HR+)/human epidermal growth factor receptor-negative (HER2-) early breast cancer (eBC) in Europe

Dose-dense adjuvant chemotherapy for primary breast cancer

Soluble interleukin-2 receptors (sIL-2R) in Hodgkin's disease: outcome and clinical implications

Clinical utility of serum HER2/neu in monitoring and prediction of progression-free survival in metastatic breast cancer patients treated with trastuzumab-based therapies

Epothilones in breast cancer : review of clinical experience: Update on epothilones - novel microtubule stabilizing agents under clinical development

Abstract PD5-04: Ki67 changes and PEPI score in the LORELEI trial: A phase II randomized, double-blind study of neoadjuvant letrozole plus taselisib versus letrozole plus placebo in postmenopausal women with ER-positive/HER2-negative early-stage breast cancer

Doxorubicin followed by sequential paclitaxel and cyclophosphamide versus concurrent paclitaxel and cyclophosphamide: 5-year results of a Phase II randomized trial of adjuvant Dose-dense chemotherapy for women with node-positive breast carcinoma

Incidence of chemotherapy‐induced, long‐term amenorrhea in patients with breast carcinoma age 40 years and younger after adjuvant anthracycline and taxane

Phase II study of gemcitabine, trastuzumab, and pertuzumab for HER2-positive metastatic breast cancer after prior pertuzumab-based therapy

Neoadjuvant letrozole plus taselisib versus letrozole plus placebo in postmenopausal women with oestrogen receptor-positive, HER2-negative, early-stage breast cancer (LORELEI): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial

Suchergebnisse filtern